Oral amyloid as a complication of myelomatosis.

L. Cahn

DOI: https://doi.org/10.1016/S0030-4220(57)80068-1

1957-07-01

Abstract:

What problem does this paper attempt to address?

Liquid biopsies: donor-derived cell-free DNA for the detection of kidney allograft injury

Michael Oellerich,Karen Sherwood,Paul Keown,Ekkehard Schütz,Julia Beck,Johannes Stegbauer,Lars Christian Rump,Philip D. Walson

DOI: https://doi.org/10.1038/s41581-021-00428-0

IF: 42.439

2021-05-24

Nature Reviews Nephrology

Abstract:In kidney transplantation, the use of minimally invasive damage biomarkers that are more sensitive and specific than plasma creatinine will be crucial to enable early, actionable detection or exclusion of structural kidney damage due to acute or chronic rejection. Donor-derived cell-free DNA (dd-cfDNA), which can be quantified, for example, through next-generation sequencing, droplet digital PCR and quantitative PCR, is a candidate biomarker with great potential for enabling comprehensive monitoring of allograft injury. dd-cfDNA has a favourable overall diagnostic performance for the detection of rejection and its high negative predictive value might be especially useful for avoiding unnecessary biopsies. Elevated dd-cfDNA levels have been shown to be detectable before graft injury can be clinically identified using current diagnostic methods. Moreover, dd-cfDNA falls rapidly to baseline levels after successful treatment for rejection owing to its short half-life. dd-cfDNA can detect graft injury caused by immune activation owing to insufficient immunosuppression and might therefore also help guide immunosuppression dosing. The fractional abundance of dd-cfDNA can be affected by changes in the recipient cfDNA (for example, due to infection or physical exercise) but the use of absolute quantification of dd-cfDNA overcomes this limitation. Serial dd-cfDNA determinations might therefore facilitate cost-effective personalized clinical management of kidney transplant recipients to reduce premature graft loss.

urology & nephrology
Prognostic Value of the Donor-Derived Cell-Free DNA Assay in Acute Renal Rejection Therapy: A Prospective Cohort Study.

Jia Shen,Luying Guo,Pengpeng Yan,Jingyi Zhou,Qin Zhou,Wenhua Lei,Haitao Liu,Guangjun Liu,Junhao Lv,Feng Liu,Hongfeng Huang,Wenzhao Dong,Liping Shu,Huiping Wang,Jianyong Wu,Jianghua Chen,Rending Wang

DOI: https://doi.org/10.1111/ctr.14053

2020-01-01

Abstract:Donor-derived cell-free DNA (dd-cfDNA) is a promising biomarker for monitoring allograft status. However, whether dd-cfDNA can reflect real-time anti-rejection treatment effects remains unclear. We prospectively recruited 28 patients with acute renal rejection, including 5 with ABMR, 12 with type IA or type IB rejection, and 11 with type IIA or IIB rejection. dd-cfDNA levels in peripheral blood were measured using human single nucleotide polymorphism (SNP) locus capture hybridization. The percentage of dd-cfDNA (dd-cfDNA%) declined significantly from 2.566 +/- 0.549% to 0.773 +/- 0.116% (P < .001) after anti-rejection therapy. The dd-cfDNA% decreased steadily over the course of 3 days with daily methylprednisolone injections, but no significant difference in the dd-cfDNA% was observed between the end of anti-rejection therapy and 2 weeks later. Changes in the dd-cfDNA% ( increment dd-cfDNA%) demonstrated a positive correlation with estimated glomerular filtration rates at 1 month (rho = 2.570,P = .022), 3 months (rho = 3.210,P = .027), and 6 months (rho = 2.860,P = .019) after therapy. Thus, the dd-cfDNA assay shows prognostic capabilities in therapy outcome and allograft recovery; however, its ability is inhibited by methylprednisolone regardless of the types of rejection. Additionally, a reassessment of frequency intervals for testing is required.
Donor-derived cell-free DNA can discriminate acute rejection types after kidney transplantation

程雅妹,郭陆英,雷文华,吕军好,严芃芃,沈佳,王美芳,周芹,王慧萍,陈江华,王仁定

DOI: https://doi.org/10.3760/cma.j.cn441217-20210305-00006

2022-01-01

Abstract:Objective:To explore the value of detecting plasma donor-derived free DNA (dd-cfDNA) fraction in distinguishing antibody mediated-rejection (ABMR) and T cell-mediated rejection (TCMR) of renal allografts.Methods:Patients with acute rejection confirmed by allograft biopsy in the First Affiliated Hospital of Medical College of Zhejiang University from December 1, 2017 to July 18, 2019 were retrospectively included. Based on pathological classification of Banff renal allograft rejection in 2017, the patients were divided into ABMR group and TCMR group, and the latter was subdivided into TCMR Ⅰ subgroup and TCMR Ⅱ subgroup. The second generation sequencing and target region capture were used to detect candidates' peripheral blood dd-cfDNA. The demographic and clinicopathological data of the two groups were compared. The receiver operating characteristic curve (ROC) was used to evaluate the differential value of plasma dd-cfDNA and serum creatinine levels in two kinds of acute renal allograft rejection.Results:A total of 60 patients with acute rejection of renal transplantation were enrolled in this study, including 42 patients in TCMR group and 18 patients in ABMR group. The plasma dd-cfDNA percentage (%) in the ABMR group was significantly higher than that in the TCMR group [2.33(1.19, 4.30)% vs 0.98(0.50, 1.82)%, P=0.001]. The absolute value of dd-cfDNA in ABMR group was obviously higher than that in TCMR group [0.94(0.60, 2.27) ng/ml vs 0.43(0.20, 0.96) ng/ml, P=0.003]. ROC analysis to discriminate TCMR from ABMR showed that, the area under the curve ( AUC) of dd-cfDNA% was 0.76(95% CI 0.64-0.88), when the threshold was 1.11%, the sensitivity and specificity were 88.89% and 59.52%, respectively; the AUC of absolute value of dd-cfDNA was 0.74(95% CI 0.61-0.86), when the threshold was 0.53 ng/ml, the sensitivity was 88.89% and the specificity was 54.76%. TCMR subgroups were further analyzed, there was no significant difference between TCMR subgroups on the absolute value and percentage of dd-cfDNA (both P>0.05); dd-cfDNA% in ABMR group was apparently higher than that in TCMRⅠ subgroups ( P=0.008) and TCMRⅡsubgroup ( P=0.030). The absolute value of dd-cfDNA in ABMR group was significantly higher than that in TCMRⅠsubgroups ( P=0.003). Conclusion:Plasma dd-cfDNA level may help to distinguish between ABMR and TCMR rejection.
Elevation of Donor-derived Cell-free DNA Before Biopsy-proven Rejection in Kidney Transplant

Jonathan S. Bromberg,Suphamai Bunnapradist,Milagros Samaniego-Picota,Sanjiv Anand,Erik Stites,Philippe Gauthier,Zachary Demko,Adam Prewett,Madeleine Armer-Cabral,Kyle Marshall,Navchetan Kaur,Michelle S. Bloom,Hossein Tabriziani,Sangeeta Bhorade,Matthew Cooper,

DOI: https://doi.org/10.1097/tp.0000000000005007

2024-04-08

Transplantation

Abstract:Background. Standard-of-care biomarkers for renal allograft rejection are lagging indicators, signaling existing organ injury. This precludes early intervention, when immunological cascades leading to rejection are most susceptible. Donor-derived cell-free DNA (dd-cfDNA) shows promise as an early indicator of rejection, allowing earlier and possibly more effective treatment. This analysis was designed to assess this promise using real-world dd-cfDNA testing evidence. Methods. This retrospective analysis of the prospective, observational ProActive registry study (NCT04091984) assessed dd-cfDNA and serum creatinine levels before biopsy in 424 patients with ≥1 dd-cfDNA test (n = 1013) in the 6 mo before biopsy. Results. Of 4667 enrolled patients, 1631 patients had ≥18 mo of follow-up data, of which 424 had a biopsy and were included in this analysis. Twenty-six biopsies showed antibody-mediated rejection (ABMR), 62 showed T cell–mediated rejection, and 336 showed nonrejection; each from a unique patient. dd-cfDNA fractions were significantly elevated 5 mo before ABMR biopsies, and 2 mo before T cell–mediated rejection biopsies, compared with nonrejection biopsies. In contrast, serum creatinine did not discriminate between rejection and nonrejection in advance, or concurrent with biopsy. Among patients with nonrejection biopsies, estimated glomerular filtration rate was significantly lower in cases with ≥2 increased dd-cfDNA results (≥1%), compared with those with 0 or 1 increased dd-cfDNA result. Conclusions. These data indicate that dd-cfDNA is an early indicator of biopsy-proven rejection, especially ABMR, suggesting a greater role for dd-cfDNA in surveillance to identify patients at high risk of ongoing or future rejection, thus requiring closer monitoring, biopsy, or other management changes.

immunology,surgery,transplantation
Early clinical experience using donor‐derived cell‐free DNA to detect rejection in kidney transplant recipients

Edmund Huang,Supreet Sethi,Alice Peng,Reiad Najjar,James Mirocha,Mark Haas,Ashley Vo,Stanley C. Jordan

DOI: https://doi.org/10.1111/ajt.15289

IF: 9.369

2019-03-29

American Journal of Transplantation

Abstract:Donor-derived cell-free DNA (dd-cfDNA) became Medicare reimbursable in the United States in October 2017 for the detection of rejection in kidney transplant recipients based on results from its pivotal validation trial, but it has not yet been externally validated. We assessed 63 adult kidney transplant recipients with suspicion of rejection with dd-cfDNA and allograft biopsy. Of these, 27 (43%) patients had donor-specific antibodies and 34 (54%) were found to have rejection by biopsy. The percentage of dd-cfDNA was higher among patients with antibody-mediated rejection (ABMR; median 1.35%; interquartile range [IQR]: 1.10%-1.90%) compared to those with no rejection (median 0.38%, IQR: 0.26%-1.10%; P < .001) and cell-mediated rejection (CMR; median: 0.27%, IQR: 0.19%-1.30%; P = .01). The dd-cfDNA test did not discriminate patients with CMR from those without rejection. The area under the ROC curve (AUC) for CMR was 0.42 (95% CI: 0.17-0.66). For ABMR, the AUC was 0.82 (95% CI: 0.71-0.93) and a dd-cfDNA ≥0.74% yielded a sensitivity of 100%, specificity 71.8%, PPV 68.6%, and NPV 100%. The dd-cfDNA test did not discriminate CMR from no rejection among kidney transplant recipients, although performance characteristics were stronger for the discrimination of ABMR.

surgery,transplantation
Cell-Free DNA for the detection of kidney allograft rejection

Olivier Aubert,Cindy Ursule-Dufait,Romain Brousse,Juliette Gueguen,Maud Racapé,Marc Raynaud,Elisabet Van Loon,Angelica Pagliazzi,Edmund Huang,Stanley C. Jordan,Kenneth D. Chavin,Gaurav Gupta,Dhiren Kumar,Tarek Alhamad,Sanjiv Anand,Jorge Sanchez-Garcia,Basmah A. Abdalla,Julien Hogan,Rouba Garro,Darshana M. Dadhania,Pranjal Jain,Didier A. Mandelbrot,Maarten Naesens,Raja Dandamudi,Vikas R. Dharnidharka,Dany Anglicheau,Carmen Lefaucheur,Alexandre Loupy

DOI: https://doi.org/10.1038/s41591-024-03087-3

IF: 82.9

2024-06-04

Nature Medicine

Abstract:Donor-derived cell-free DNA (dd-cfDNA) is an emerging non-invasive biomarker that has the potential to detect allograft injury. The capacity of donor-derived cell-free DNA to detect kidney allograft rejection and its added clinical value beyond standard of care patient monitoring is unclear. We enrolled 2,882 kidney allograft recipients from 14 transplantation centers in Europe and the US in an observational population-based study. The primary analysis included 1,134 patients. Donor-derived cell-free DNA levels strongly correlated with allograft rejection including antibody-mediated rejection (p < 0.0001), T-Cell mediated rejection (p < 0.0001) and mixed rejection (p < 0.0001). In multivariable analysis, circulating dd-cfDNA was significantly associated with allograft rejection (OR: 2.275; CI:1.902–2.739; p < 0.0001) independently of standard of care patient monitoring parameters. The inclusion of dd-cfDNA to a standard of care prediction model showed improved discrimination (0.777 [95% CI: 0.741–0.811] to 0.821 [95% CI: 0.784–0.852]; p = 0.0011) and calibration. These results were confirmed in the external validation cohorts (n = 1,748) including a cohort of African American patients (n = 439). Finally, dd-cfDNA showed high predictive value to detect subclinical rejection in stable patients. Our study provides insights on the potential value of assessing dd-cfDNA, in addition to standard of care monitoring, to improve the detection of allograft rejection. ClinicalTrials.gov registration: NCT05995379.

biochemistry & molecular biology,cell biology,medicine, research & experimental
Benign lymphocytic angiitis and granulomatosis: experience with three cases.

Douglas R. Gracey,R. Deremee,Thomas V. Colby,K. Unni,Louis H. Weiland

DOI: https://doi.org/10.1016/S0025-6196(12)64852-6

IF: 11.104

1988-04-01

Mayo Clinic Proceedings

Abstract:
Dynamics of Early Post-Operative Plasma Ddcfdna Levels in Kidney Transplantation: a Single-Center Pilot Study.

Jia Shen,Yang Zhou,Yawen Chen,Xiaofeng Li,Wenhua Lei,Jun Ge,Wenhan Peng,Jianyong Wu,Guangjun Liu,Gongda Yang,Haifeng Shi,Jianghua Chen,Tingya Jiang,Rending Wang

DOI: https://doi.org/10.1111/tri.13341

2018-01-01

Transplant International

Abstract:Donor-derived cell-free DNA (ddcfDNA) is reported to be a promising noninvasive biomarker for acute rejection in organ transplant. However, studies on monitoring ddcfDNA dynamics during the early periods after organ transplantation are scarce. Our study assessed the dynamic variation in ddcfDNA in early period with various types and status of kidney transplantation. Target region capture sequencing used identifies ddcfDNA level in 21 kidney transplant recipients. Median ddcfDNA level was 20.69% at the initial time post-transplant, and decreased to 5.22% on the first day and stayed at the stable level after the second day. The ddcfDNA level in DCD (deceased donors) group (44.99%) was significantly higher than that in LDRT (living donor) group (10.24%) at initial time, P DNA level in DGF (delayed graft function) recipients was lower (23.96%) than that in non-DGF (47.74%) at the initial time, P = 0.89 (19.34% in DGF and 4.46% in non-DGF on the first day, P = 0.17). DdcfDNA level at initial time significantly correlated with serum creatinine (r(2) = 0.219, P = 0.032) and warm ischemia time (r(2) = 0.204, P = 0.040). Plasma ddcfDNA level decreased rapidly follow an L-shaped curve post-transplant, and level in DGF declined slower than non-DGF. The rebound of ddcfDNA level may indicate the occurrence of acute rejection.
An Assessment of the Value of Donor-derived Cell-free DNA Surveillance in Patients With Preserved Kidney Allograft Function

Edmund Huang,Mark Haas,Matt Gillespie,Supreet Sethi,Alice Peng,Reiad Najjar,Ashley Vo,Stanley C. Jordan

DOI: https://doi.org/10.1097/tp.0000000000004267

2022-12-22

Transplantation

Abstract:Donor-derived cell-free DNA (dd-cfDNA) is a novel biomarker that is gaining traction in kidney transplantation as a predictor of allograft rejection and injury and is now used by over 160 transplant centers across the United States. 1 However, its clinical utility in kidney transplantation remains undefined. Early data suggested that dd-cfDNA could be used to detect the presence of rejection on histology, 2 , 3 but its inability to discriminate T cell–mediated rejection raised concern that reliance on dd-cfDNA alone could miss cases of rejection. 4 Despite its limitations, many transplant programs have implemented routine dd-cfDNA surveillance protocols to screen for subclinical rejection and injury without sufficient data to support its use in this fashion. Of additional concern, the practice has extended beyond transplant programs to community providers which could lead to overutilization of dd-cfDNA testing in settings without proven clinical benefit. 5

immunology,surgery,transplantation
Analysis of the primary factors influencing donor derived cell-free DNA testing in kidney transplantation

Changling Cao,Li Yuan,Yinfeng Wang,Haitao Liu,Haider Cuello Garcia,Huiqiang Huang,Weiqiang Tan,Yang Zhou,Haifeng Shi,Tingya Jiang

DOI: https://doi.org/10.3389/fimmu.2024.1435578

2024-09-06

Abstract:The donor-derived cell-free DNA (ddcfDNA) is found in the plasma and urine of kidney transplant recipients and displays notable potential in diagnosing rejection, specifically antibody-mediated rejection (ABMR). Nonetheless, the quantitative methods of ddcfDNA lacking standardization and diverse detection techniques can impact the test outcomes. Besides, both the fraction and absolute values of ddcfDNA have been reported as valuable markers for rejection diagnosis, but they carry distinct meanings and are special in various pathological conditions. Additionally, ddcfDNA is highly sensitive to kidney transplant injury. The various sampling times and combination with other diseases can indeed impact ddcfDNA detection values. This review comprehensively analyses the various factors affecting ddcfDNA detection in kidney transplantation, including the number of SNPs and sequencing depths. Furthermore, different pathological conditions, distinct sampling time points, and the presence of complex heterologous signals can influence ddcfDNA testing results in kidney transplantation. The review also provides insights into ddcfDNA testing on different platforms along with key considerations.
Combining donor-derived cell-free DNA and donor specific antibody testing as non-invasive biomarkers for rejection in kidney transplantation

Bogdan Obrișcă,Maria Butiu,Lena Sibulesky,Ramasamy Bakthavatsalam,Kelly D Smith,Idoia Gimferrer,Paul Warner,Gener Ismail,Nicolae Leca

DOI: https://doi.org/10.1038/s41598-022-19017-7

2022-09-05

Abstract:Donor specific anti-HLA antibodies (DSA) and donor-derived cell-free DNA (dd-cfDNA) have lead to substantial progress in the non-invasive monitoring of the renal allograft by being able to detect or rule out subclinical rejection and guide immunosuppressive changes. In this study we sought to analyze the clinical, de novo DSA (dnDSA) and histological determinants of dd-cfDNA levels. The study included a cohort of stable renal function kidney transplant (KT) recipients who underwent anti-HLA dnDSA and dd-cfDNA testing between September 2017-December 2019. Statistical models were constructed to detect association with predictors of dd-cfDNA levels and other clinical characteristics. 171 renal allograft recipients were tested for dd-cfDNA and dnDSA at a median 1.06 years posttransplant (IQR: 0.37-4.63). Median dd-cfDNA was 0.25% (IQR: 0.19-0.51), 18.7% of patients having a dd-cfDNA ≥ 1%. In a multivariate linear regression model the presence of dnDSA MFI ≥ 2500 was the best independent determinant of dd-cfDNA level (p < 0.001). Among patients tested, 54 had concurrent dd-cfDNA determination at the time of an allograft biopsy. dd-cfDNA had an AUC of 0.82 (95% CI 0.69-0.91; p < 0.001) and of 0.96 (95% CI 0.87-0.99) to discriminate any rejection and ABMR, respectively. After multivariate adjustment, the models that included ABMR (R = 0.82, R2 = 0.67, p < 0.001), or ptc (R = 0.79, R2 = 0.63, p < 0.001) showed the best correlation with dd-cfDNA level. We are confirming a strong association of dd-cfDNA with dnDSA and underlying alloimmune-mediated injury in renal allograft recipients in a cohort of patients with unsuspecting clinical characteristics for rejection and excellent allograft function. Our findings support the need for noninvasive biomarker surveillance in KT recipients and we propose that dd-cfDNA may complement dnDSA screening.
Donor-Derived Cell-free DNA for Personalized Immunosuppression in Renal Transplantation

Michael Oellerich,Klemens Budde,Bilgin Osmanodja,Kirsten Bornemann-Kolatzki,Julia Beck,Ekkehard Schütz,Philip D Walson

DOI: https://doi.org/10.1097/FTD.0000000000001023

2023-02-01

Abstract:Background: The long-term outcomes of solid organ transplantation remain suboptimal. Therefore, appropriate biomarkers are needed in addition to immunosuppressive drugs and other traditional approaches for graft monitoring to achieve personalized immunosuppression and reduce premature graft loss. Methods: Donor-derived cell-free DNA (dd-cfDNA) is a minimally invasive biomarker of cell death due to graft injury. It can be quantified using droplet digital polymerase chain reaction and next-generation sequencing. Fractional dd-cfDNA determination can be affected by changes in recipient cfDNA, such as those caused by leukopenia or infection, leading to false-positive or false-negative results, respectively. Absolute quantification of dd-cfDNA helps in overcoming this limitation. Results: Overall, there is sufficient evidence of the clinical validity of dd-cfDNA. It detects rejection episodes early at an actionable stage and reflects the severity of graft injury without being rejection-specific. Owing to its high negative predictive value, dd-cfDNA is very useful for ruling out graft injury. Dd-cfDNA complements histological findings and can help in avoiding unnecessary biopsies. It indicates a response to rejection treatment and detects underimmunosuppression. Conclusions: Monitoring changes in dd-cfDNA over time may be helpful in adapting immunosuppression to prevent graft rejection. Moreover, serial dd-cfDNA determination may increase the effectiveness of transplant recipient surveillance and facilitate personalized immunosuppression when combined with other relevant clinical and diagnostic findings.
Donor-derived cell-free DNA: An independent biomarker in kidney transplant patients with antibody-mediated rejection

Dongrui Cheng,Feng Liu,Kenan Xie,Caihong Zeng,Xue Li,Xuefeng Ni,Jun Ge,Lipin Shu,Yang Zhou,Haifeng Shi,Haitao Liu,Jinsong Chen

DOI: https://doi.org/10.1016/j.trim.2021.101404

IF: 2.032

2021-01-01

Transplant Immunology

Abstract:Introduction: Antibody-mediated rejection (ABMR) is a major cause of kidney transplant failure which requires donor-specific antibodies (DSA) for a definitive diagnosis. Donor-derived cell-free DNA (ddcfDNA) is an emerging biomarker used to assess kidney allograft injury. However, current data is limited to predict the accuracy of ddcfDNA in ABMR diagnosis. This study was conducted to compare the performance of DSA with plasma ddcfDNA for the diagnosis of ABMR. Methods: In this retrospective single-center observational study, we enrolled 50 kidney transplant recipients who were diagnosed with the suspicion of rejection between June 2018 and May 2019 at the Jinling Hospital. Plasma ddcfDNA was measured by using a novel target region capture sequencing methodology. A total of 37 patients who were tested with DSA and biopsy were divided into four subgroups (ABMR+/DSA+, ABMR+/DSA-, ABMR-/ DSA+, ABMR-/DSA-) for the distribution of ddcfDNA (%) by ABMR and DSA. Results: The median level of ddcfDNA in biopsy showed that the ABMR group (1.66%, IQR 1.34-3.76%) was significantly higher than the median level (0.63%, IQR 0.43-0.74%) in non-ABMR (p < 0.001). With a ddcfDNA cutoff of 0.96%, the AUC was 0.90 (95%CI, 0.86-0.95), which was associated with a sensitivity of 90.5% (95%CI, 69.6-98.8%) and specificity of 96.6% (95%CI, 82.2-100%), a PPV of 95% (95%CI, 73.4-99.2%) and NPV of 93.3% (95%CI, 78.9-98.1%) were also observed. Among the four subgroups, ddcfDNA had no significant difference in both DSA+ group and DSA-group (p > 0.05). In the diagnosis of ABMR, the specificity, sensitivity, PPV and NPV of DSA were 50%, 74.1%, 41.7%, 80%, respectively. Conclusions: ddcfDNA levels in the blood could highly distinguish (biopsy-supported) ABMR occurrence, irrespective of whether this method is accompanied by DSA or not.
Perspective for Donor-Derived Cell-Free DNA in Antibody-Mediated Rejection After Kidney Transplantation: Defining Context of Use and Clinical Implications

Aylin Akifova,Klemens Budde,Michael Oellerich,Julia Beck,Kirsten Bornemann-Kolatzki,Ekkehard Schütz,Bilgin Osmanodja

DOI: https://doi.org/10.3389/ti.2024.13239

2024-08-12

Abstract:Antibody-mediated rejection (AMR) is a major cause of graft failure limiting long-term graft survival after kidney transplantation. Current diagnostic strategy to detect AMR is suboptimal and requires further improvement. Previously suggested treatment regimens for AMR could not demonstrate efficacy, however novel therapeutic agents are currently under investigation. Donor-derived cell-free DNA (dd-cfDNA) is a novel non-invasive biomarker for allograft injury, that has been mainly studied in the context of rejection. Its short-half-life in circulation and injury-dependent release are its key advantages that contribute to its superior diagnostic accuracy, compared to traditional biomarkers. Moreover, previous studies showed that dd-cfDNA-release is well-linked to histological and molecular features of AMR, and thus able to reflect real-time injury. Further observations suggest that dd-cfDNA can be used as a suitable screening tool for early detection of AMR in patients with donor-specific-anti-HLA-antibodies (DSA), as well as for monitoring AMR activity after anti-rejection treatment. The weight of evidence suggests that the integration of dd-cfDNA in the graft surveillance of patients with AMR, or those suspicious of AMR (e.g., due to the presence of donor-specific anti-HLA-antibodies) has an added value and might have a positive impact on outcomes in this specific cohort.
Donor-derived cell-free DNA predicted allograft rejection and severe microvascular inflammation in kidney transplant recipients

Hyung Duk Kim,Hyunjoo Bae,Hyunhye Kang,Hanbi Lee,Sang Hun Eum,Chul Woo Yang,Yeong Jin Choi,Byung Ha Chung,Eun-Jee Oh

DOI: https://doi.org/10.3389/fimmu.2024.1433918

2024-07-09

Abstract:Introduction: The aim of this study is to investigate the clinical validity of donor-derived cell-free DNA (dd-cfDNA) in comparison with that of donor specific anti-HLA antibody (DSA) for predicting biopsy-proven rejection (BPR)and severe microvascular inflammation (severe MVI) in kidney transplant recipients (KTRs). Methods: In this prospective observational investigation, 64 KTRs who underwent the indicated biopsies were included. Blood samples collected prior to biopsy were tested for dd-cfDNA and DSA. Biopsy specimens were classified by a renal pathologist according to the Banff classification. The predictive performance of dd-cfDNA and DSA for histological allograft diagnosis was assessed. Results: KTRs were categorized into the high and low dd-cfDNA groups based on a level of 0.4%. Eighteen patients (28.1%) had positive DSA at biopsy, exhibiting higher dd-cfDNA levels than the DSA-negative patients. BPR and severe MVI incidences were elevated in the high dd-cfDNA group (BPR: 42.9% vs. 3.4%, P <0.001; severe MVI: 37.1% vs. 3.4%, P = 0.001). Also, elevated glomerulitis and MVI scores were observed in the high dd-cfDNA group. DSA showed the highest predictive value for BPR (AUC = 0.880), whereas dd-cfDNA alone excelled in predicting severe MVI (AUC = 0.855). Combination of DSA and dd-cfDNA (>0.4%) yielded sensitivities of 80.0% and 50.0% with specificities of 90.7% and 88.0% for antibody-mediated rejection and severe MVI detection, respectively. Conclusion: The dd-cfDNA test is a predictive tool for BPR and severe MVI, and it can improve the performance, especially when combined with DSA for BPR.
Effects of teat number on litter size in gilts.

Ju-Sung Kim,D. Jin,Jun Heon Lee,D. Son,Seong Ho Lee,Yoon-Sun Yi,C. Park

DOI: https://doi.org/10.1016/J.ANIREPROSCI.2005.01.013

IF: 2.22

2005-11-01

Animal Reproduction Science

Abstract:
Early Monitoring of Donor-Derived Cell-Free DNA in Kidney Allograft Recipients Followed-Up for Two Years: Experience of One Center

Carmen Botella,José Antonio Galián,Víctor Jiménez-Coll,Marina Fernández-González,Francisco Morales,Gloria Martínez-Gómez,Rosana González-López,María José Alegría,María Rosa Moya,Helios Martinez-Banaclocha,Alfredo Minguela,Isabel Legaz,Santiago Llorente,Manuel Muro

DOI: https://doi.org/10.3390/life14111491

2024-11-23

Life

Abstract:(1) Background: donor-derived circulating free DNA (dd-cfDNA), an innovative biomarker with great potential for the early identification and prevention of graft damage. (2) Methods: Samples were collected prospectively and the study was performed retrospectively to analyze dd-cfDNA plasma levels in 30 kidney transplant patients during their post-transplant follow-up (15 days, 3, 6, and 9 months), to determine if the result could be of interest in the identification of possible adverse events, especially rejection. The aim was to verify whether the data on sensitivity, specificity, NPV, and PPV compare with reference values and creatinine values. (3) Results: We observed levels of dd cfDNA > 1% in six of nine patients with active rejection (ABMR or TCMR) and elevated values (>0.5%) in two other patients in this rejection group. Our results show low values of sensitivity = 50%, specificity = 61.11%, rejection NPV = 64.71%, and rejection PPV = 46.13% of the technique compared to reference values previously published. With respect to creatinine, only for TCRM, we observed better results for dd-cfDNA in these parameters than in creatinine. Also, our data suggest that dd-cfDNA could help to differentiate those patients with dnDSAs that are going to through rejection better than creatinine, specially at 15 d post transplant. In this study, this appears to have no positive predictive value for borderline rejection (BR) or TCMR IA. (4) Conclusions: plasma levels of dd-cfDNA could be considered an additional or alternative biomarker for graft rejection monitoring in early post-kidney transplant up to several months before its clinical presentation, especially for patients with suspected TCMR or ABMR.

biology
Understanding Donor-derived Cell-free DNA in Kidney Transplantation: An Overview and Case-based Guide for Clinicians

Alison S Graver,Darren Lee,David A Power,John B Whitlam

DOI: https://doi.org/10.1097/TP.0000000000004482

2023-08-01

Transplantation

Abstract:Kidney transplant recipients undergo lifelong monitoring of allograft function and evaluation for transplant complications. The current monitoring paradigm utilizes blood, urine, and tissue markers that are insensitive, nonspecific, or invasive to obtain. As a result, problems are detected late, after significant damage has accrued, and often beyond the time at which complete resolution is possible. Indeed, most kidney transplants eventually fail, usually because of chronic rejection and other undetected injury. There is a clear need for a transplant-specific biomarker that enables a proactive approach to monitoring via early detection of reversible pathology. A biomarker that supports timely and personalized treatment would assist in achieving the ultimate goal of improving allograft survival and limiting therapeutic toxicity to the recipient. Donor-derived cell-free DNA (ddcfDNA) has been proposed as one such transplant biomarker. Although the test is presently utilized most in the United States, it is conceivable that its use will become more widespread. This review covers aspects of ddcfDNA that support informed use of the test by general nephrologists, including the basic biology of ddcfDNA, methodological nuances of testing, and general recommendations for use in the kidney transplant population. Clinical contexts are used to illustrate evidence-supported interpretation of ddcfDNA results and subsequent management. Finally, knowledge gaps and areas for further study are discussed.
Donor Plasma Mitochondrial DNA is Associated with Antibody-Mediated Rejection in Renal Allograft Recipients

Fei Han,Qipeng Sun,Zhengyu Huang,Heng Li,Maolin Ma,Tao Liao,Zihuang Luo,Lingling Zheng,Nana Zhang,Nan Chen,Liangqing Hong,Ning Na,Qiquan Sun

DOI: https://doi.org/10.18632/aging.202654

2021-01-01

Aging

Abstract:We previously showed that donor plasma mitochondrial DNA (dmtDNA) levels were correlated with renal allograft function. The aim of the current study was to determine whether dmtDNA levels are associated with the occurrence of antibody-mediated rejection (ABMR). This is a retrospective open cohort study comprised of 167 donors and 323 recipients enrolled from January 2015 to December 2017. We quantified the mtDNA level present in donor plasma using quantitative real-time polymerase chain reaction. The average plasma dmtDNA level in the acute rejection (AR) group was higher than that of the control group (0.156 versus 0.075, p<0.001). Multivariate logistic regression analysis showed that dmtDNA levels were also significantly associated with AR (OR=1.588, 95% CI 1.337-4.561, p<0.001). When the dmtDNA level was >0.156, the probability of AR was 62.9%. The plasma dmtDNA level in the ABMR group was significantly higher than that of the T cell-mediated rejection group (0.185 versus 0.099, p=0.032). The area under the receiver operating characteristic curve of dmtDNA for prediction of ABMR was as high as 0.910 (95% CI 0.843-0.977). We demonstrated that plasma dmtDNA was an independent risk factor for ABMR, which is valuable in organ evaluation. dmtDNA level is a possible first predictive marker for ABMR.
The role of donor-derived cell-free DNA in the detection of renal allograft injury

Yang Zhou,Dongrui Cheng,Tingya Jiang

DOI: https://doi.org/10.1016/j.nephro.2020.10.003

Abstract:Donor-derived cell-free DNA refers to the cell-free DNA derived from apoptosis or necrosis of allograft tissue, circulating in the body fluids of patients after organ transplantation, and carries health information on the donor tissue. In the past two years, donor-derived cell-free DNA has rapidly become a research hotspot in the field of graft rejection detection after organ transplant. Recent published data have increased our understanding of donor-derived cell-free DNA in the field of kidney transplantation, especially in association with acute rejection. Donor-derived cell-free DNA is predicted to become the next-generation biomarker for the non-invasive detection of allograft rejection. This article reviews the research, involving donor-derived cell-free DNA in ischemia-reperfusion injury, delayed graft function, acute rejection (antibody mediated rejection and T-cell mediated rejection), and BK virus nephropathy. We further discuss the limitations of current research models and suggest directions for future study.

Oral amyloid as a complication of myelomatosis.

Liquid biopsies: donor-derived cell-free DNA for the detection of kidney allograft injury

Prognostic Value of the Donor-Derived Cell-Free DNA Assay in Acute Renal Rejection Therapy: A Prospective Cohort Study.

Donor-derived cell-free DNA can discriminate acute rejection types after kidney transplantation

Elevation of Donor-derived Cell-free DNA Before Biopsy-proven Rejection in Kidney Transplant

Early clinical experience using donor‐derived cell‐free DNA to detect rejection in kidney transplant recipients

Cell-Free DNA for the detection of kidney allograft rejection

Benign lymphocytic angiitis and granulomatosis: experience with three cases.

Dynamics of Early Post-Operative Plasma Ddcfdna Levels in Kidney Transplantation: a Single-Center Pilot Study.

An Assessment of the Value of Donor-derived Cell-free DNA Surveillance in Patients With Preserved Kidney Allograft Function

Analysis of the primary factors influencing donor derived cell-free DNA testing in kidney transplantation

Combining donor-derived cell-free DNA and donor specific antibody testing as non-invasive biomarkers for rejection in kidney transplantation

Donor-Derived Cell-free DNA for Personalized Immunosuppression in Renal Transplantation

Donor-derived cell-free DNA: An independent biomarker in kidney transplant patients with antibody-mediated rejection

Perspective for Donor-Derived Cell-Free DNA in Antibody-Mediated Rejection After Kidney Transplantation: Defining Context of Use and Clinical Implications

Donor-derived cell-free DNA predicted allograft rejection and severe microvascular inflammation in kidney transplant recipients

Effects of teat number on litter size in gilts.

Early Monitoring of Donor-Derived Cell-Free DNA in Kidney Allograft Recipients Followed-Up for Two Years: Experience of One Center

Understanding Donor-derived Cell-free DNA in Kidney Transplantation: An Overview and Case-based Guide for Clinicians

Donor Plasma Mitochondrial DNA is Associated with Antibody-Mediated Rejection in Renal Allograft Recipients

The role of donor-derived cell-free DNA in the detection of renal allograft injury